Dr Tolaney on Data With Checkpoint Inhibitor Combinations in Metastatic TNBC

Sara M. Tolaney, MD, MPH, chief, Division of Breast Oncology, associate director, Susan F. Smith Center for Women’s Cancers; senior physician, Dana-Farber Cancer Institute, associate professor, medicine, Harvard Medical School, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer (TNBC).
Website: www.onclive.com
Twitter: / onclive
Facebook: / onclive
LinkedIn: / onclive